

Register by 15 Jan and save USD\$700! Booking form on back page.

1-3
March
2011

- 150+** Vaccine industry decision makers from India & worldwide
 - 40+** Speakers
 - 25** Hours of networking
 - 3** Days of learning & networking
 - 2** Conferences
- *All in 1 location!*

Vaccine

Business, technology & Innovation

World Summit 2011

1 -3 March 2011, Raddison Hotel Delhi, New, Delhi, India

India's No. 1 Vaccine Conference

Distinguished Speaker Faculty Include:

NGO and Government



Sri Prasanna Kumar Pradhan
Additional Secretary & Mission Director, National Rural Health Mission, India



Shirshendu Mukherjee
Strategic Advisor R&D Initiative, Wellcome Trust, India



Arun Bharadwaj
Director, National Control Laboratory Kasauli, India



Dr Michael Callahan MD
Director, Emergency Vaccine Manufacturing, DARPA, USA

International Vaccine Leaders



Dr Jacques Cholat
Vice President Commercial Operations - International Sanofi Pasteur, France



Dr. B.G. Rhee
President, Green Cross Corporation, Korea



Dr Lakshmi Khandke
Director, Pfizer Vaccine Research, USA



Dr. Josemund Menezes
Regional Director, Clinical Development (Asia-Pac), Sanofi-Pasteur, India

Indian Vaccine Manufacturers



K V Balasubramaniam
Managing Director, Indian Immunologicals, India



Krishna M. Ella
Chairman & Managing Director, Bharat Biotech International Limited, India



Dr Reinhard Gluck
CSO, Zydus Cadila, India



Mahima Datta
SVP Biotechnology & projects, Biological E, India

Vaccine Research Leaders



Dr Anders Fomsgaard
Chief of Molecular Virology Laboratory, Statens Serum Institut, Denmark



Dr. Niranjn Y. Sardesai
Senior Vice President, Research & Development, Inovio Pharmaceuticals



Prof. Rajiv Khanna
Director, Australian Centre for Vaccine Development, Australia



Mae Shieh
Business Development & Partnerships, Novartis Vaccines Institute for Global Health, Italy

Event Partner:



Platinum Sponsor:



Session Sponsors:



Created & Produced by:



Letter from the Chairman

Dear friends and colleagues,

It's my sincere pleasure to welcome you to Vaccine World Summit 2011, which will be held in New Dehli in India from 1 - 3 March 2011. The event is organized in conjunction with the Developing Countries Vaccine Manufacturers Network and managed by IMAPAC. Over 35 world class speakers will be sharing their experiences and knowledge, together we will have a great opportunity to share ideas and discuss current trends in the rapidly growing vaccine industry.

Being part of the vaccine industry gives each of us the ability to change the lives of many thousands or millions of people we have never met. It is an honour, a responsibility, and a pleasure to help relieve the unnecessary suffering caused by disease and ill health, and to perform a very significant service to the entire world population.

While our work has already transformed many lives, we should not forget that over 9.5 million people die each year due to infectious diseases - nearly all live in developing countries. Together we can improve this situation. Which is why I encourage you to be part of the Vaccine World Summit, we welcome all public health professionals, NGOs, vaccine business leaders, academics and all other related stakeholders to be part of this global vaccine event.

The inaugural conference will focus on the latest success strategies for vaccines in India and the rest of the world, innovative manufacturing technologies, research funding and novel vaccines. The underlying goals are to increase the availability of life saving vaccines, decrease the cost of these vaccines and work together to find a cure for the disease that continue to pose a threat to our health, welfare and happiness.

I am looking forward to seeing each and everyone of you to join us next March in New Dehli. Let's talk, and listen together so we can share exciting new ideas, stimulate growth of the vaccine industry and improve lives of people worldwide.

Sincerely



Dr Reinhard Glück, Zydus Cadila, India

Advisory Board:



Suresh Jadhav
Executive Director, Serum Institute of India, India



Bakulesh Khamar
Executive Director, Research, Cadila Pharmaceuticals, India



Prof Nikolai Petrovsky
Research Director Vaxine, Australia



Jaques Francois Martin
CEO Parteurop, Mymetics, France

Dr V K Srinivas
Head of Quality Assurance, Bharat Biotech International, India

Event at a glance

March 1st, Tue	March 2nd, Wed		March 3rd, Thur
			
Global and Indian influenza market updates & strategies	India vaccine leaders panel & immunization strategies		Vaccine Distribution & cold chain solutions in the developing world
Networking & Morning Refreshments	Speed Networking & Morning Refreshments		Networking & Morning Refreshments
Innovations in influenza vaccines	Vaccine regulations		Vaccine Research & Innovation forum
Networking Lunch	Networking Lunch & Exhibition Visit		Networking Lunch & Exhibition Visit
	Manufacturing Stream	Adjuvants & delivery stream	
Innovations in adjuvants & delivery systems for influenza vaccines	Vaccine Manufacturing & Production I	Adjuvants	Funding for vaccine research, innovation
Afternoon Refreshments & Exhibition Visit	Afternoon Refreshments & Exhibition Visit		Afternoon Refreshments & Exhibition Visit
Pandemic & seasonal flu preparedness	Vaccine Manufacturing & Production II	Delivery Systems	Vaccine Research & Innovation forum
Closing Plenary: Was H1N1/09 the wakeup call for the next pandemic			Closing Plenary: Creating a road map for the next 5-10 years of India's vaccine industry
	Welcome Cocktail Party		
	Exhibition and Showcases		

9.00 **Organizer's welcome remarks**

9.05 **Chairman's opening remarks**
Nikolai Petrovsky, Chairman, Vaxine, Australia

Indian Influenza Market Update and Strategies

9.10 **Opening Keynote: The influenza vaccine market of India**
Keynote

- Opportunities and challenges of the Asia flu vaccine market
- Market size, trend, drivers, competitive landscape and market growth dynamics in India
- Status of international players vs. status of local players in India

Jacques Cholat, Vice President, Commercial Operations- International, Sanofi Pasteur, France

9.40 **Getting ahead of the competition: What it takes to be the first domestic player to launch H1N1 vaccine?**
Keynote

- Speed to market: Streamline the decision making and development process to successfully deliver VaxiFlu-S to the market
- Innovative marketing strategy: Targeting the corporate market niche

Reinhard Gluck, CSO, Zydus Cadila, India

10.10 **Opening debate: Indian Influenza market: Here today, gone tomorrow or not?**

- Is seasonal flu vaccine a permanent cultural shift or a fad?
- Potential market segmentations & forecasted demand for influenza vaccines in the long term
- National influenza pandemic surveillance program for the recent pandemic: lessons learnt and actions forward
- Live vote from the audience: India's influenza vaccine demand will go up or down in the near future?

Panelists:

Reinhard Gluck, CSO, Zydus Cadila, India
B.G. Rhee, President, Green Cross Corporation, Korea

Jacques Cholat, Vice President, Commercial Operations- International, Sanofi Pasteur, France
Nagendra Hegde, Group leader of Virology, Ella Foundation, India

10.50 **Morning refreshment**

Influenza Vaccine Innovation

11.20 **The promises and challenges of developing a DNA based influenza**

- Advantages of DNA technology vs. traditional approach
- Challenges in designing and developing a viable delivery system
- Latest clinical results

Anders Fomsgaard, Department of Virology, Statens Serum Institut, Denmark

11.50 **Clinical progress towards development of a universal flu vaccine**

- Possible approaches that could be taken to create a universal flu vaccine
- Strategic and regulatory considerations for the development and ultimate commercialization of the universal flu vaccine

- Implications of universal vaccines for infections diseases and their impact on global health

Niranjan Sardesai, SVP R&D, Inovio, USA

12.20 **Networking luncheon and themed roundtable discussions**

Innovation in Adjuvants and Delivery Systems

14.00 **Using adjuvants to boost global vaccine capacity as well as the immune response**

- What adjuvants are readily available to developing world manufacturers during a pandemic situation
- How much extra capacity do adjuvants really give us, is it enough for a global pandemic?
- Case study of using a novel adjuvant to boost the efficacy of a H1N1 vaccine

Nikolai Petrovsky, Chairman, Vaxine, Australia

14.30 **The way to successful intranasal vaccine delivery -What's important for intranasal vaccine delivery?**

- Cost implications Vs health implications of needle borne diseases, and how this comparison fairs in the developing world
- Selecting an appropriate delivery device

Degenhard Marx, Associate Director Business Development, Prescription Division, Aptar Pharma, Germany

15.00 **Afternoon refreshment**

Pandemic Flu and Seasonal Flu Preparedness

15.30 **Pandemic preparedness challenges for India and the rest of world in 2011**
Panel Discussion

- Lessons learned from H1N1/09
- Immediate and long-term challenges which need to be addressed in order to combat a future pandemic
- Should H1N1/09 have been declared a pandemic
- Ensuring surveillance and accurately identifying strains
- To stock pile or pre-emptive vaccination what is the best route

Panelists:

L. S. Chauhan, Director, National Centre for Disease Control, India

Nihal Abeysinghe, Regional Advisor, Vaccine Preventable Diseases, World Health Organization, South-East Asia Region, India

16.10 **Innovative, localized and portable manufacturing solutions to be pandemic ready whenever and wherever**

- Is there adequate global capacity; if not is it a viable business proposal to build it?
- Making facilities more flexible in order to cope with pandemics

16.40 **Manufacturing pandemic flu vaccines in cell culture vs. egg in developing countries: Which system provides more promises in the long run?**

- Pros and cons of cell culture vs. eggs
- Which system best suits India?

Nagendra Hegde, Group leader of Virology, Ella Foundation, India

17.10 **Chairman closing remarks:**
Nikolai Petrovsky, Chairman, Vaxine, Australia

9.00 Guest of honor:
Sri P.K.Pradhan, Additional Secretary and Mission Director, *National Rural Health Mission, India*

9.05 Chairman's opening remarks,
Reinhard Gluck, *CSO, Zydus Cadila, India*

India vaccine leaders panel & immunization strategies

9.10 Chair - Dr. V. K. Vinayak, Chief Scientific Officer, *Panacea Biotec*

9.50 Strategising the best fit Universal Immunisation Program for India
Guest speaker

- The challenges of co-ordinating on the world's biggest immunisation program
- The challenges of selecting the optimal vaccination schedule and which diseases to target
- Strategising future developments in the Universal Immunisation Program

Sri P.K.Pradhan, Additional Secretary and Mission Director, *National Rural Health Mission, India*

10.20 Speed Networking and Refreshment

Vaccine Regulations

10.50 Painting a clearer picture for vaccine regulatory pathway

- Examine the existing vaccine approval procedure in India
- Roles and responsibilities of Kasauli and CDSCO

Arun Bharadwaj, Director, *National Control laboratory Kasauli, India*

11.20 International regulations and WHO pre-qualification

- Preparing a vaccine for FDA, EMEA licensure
- WHO prequalification and the challenges of maintaining prequalification
- Case studies of recent successes and failures

12.00 Networking Lunch

Breakout Stream A

Vaccine Manufacturing & Production I

13.30 Vaccine Security: Building Technologies to Ensure Health Autonomy for All Nations

- Ensuring that all nations have access to cheap and abundant vaccines
- Review of new low cost vaccine manufacturing technologies
- Subunit vaccine expression technologies

Michael Callahan MD, Director, *Emergency Vaccine Manufacturing, DARPA, USA*

14.00 Trends in Vaccine Development

- Conventional vaccine lack immunogenicity & acceptable levels of protection. These have several adverse reactions & require cold chain for storage
- Easy vaccine targets have been exploited and conventional/classical vaccines have been employed as a part of childhood immunization that has resulted in prevention of several fatal infections
- Newer vaccines are being developed for infections by utilizing molecular strategies, understanding host: pathogen interactions and exploitation genomic informations

- Challenge: revolutionary vaccines are needed to combat life threatening infections that are emerging & assuming pandemic dimensions and to control deadly bio-weapon pathogens

- Way Forward: use of genomic information for better/efficacious vaccines

Dr. V. K. Vinayak, Chief Scientific Officer, *Panacea Biotec*

14.30 Evaluating Platform Technologies for Vaccine Purification Processes

- How standardising the manufacturing processes can reduce the time-to-market of a vaccine
- Recombinant viruses and VLPs and how they effect the upstream and downstream processes
- Single use technology and the flexibility it provides for vaccine manufacturing

Annelies Onraedt, Global Market Manager Vaccine, *Pall Life Sciences, Switzerland*

15.00 Afternoon refreshment

Vaccine Manufacturing & Production II

15.30 Managing cost-of-goods: secrets of manufacturing affordable vaccines for developing countries

- Working with trusted partners
- Key work practices
- Choosing the right technologies

Mahima Datla, SVP Biotechnology and projects, *Biological E, India*

16.00 Case study: Planning, constructing and validating a new VLP vaccine facility in India

- Design layout and operating philosophy
- Site and equipment selection
- Technology transfer
- Validation and commissioning

Sudeep Srivastava, General Manager - Biotechnology, *CPL Biologicals, India*

16.30 Media Supplementation for Vaccine Production - Lessons Learned and a Look Ahead

Matthias Brand, Market Development Manager, *Advanced Bioprocessing, BD, Singapore*

17.00 Management of Bio-containment Facilities for the safe manufacture and testing of 'Foot and Mouth Disease' Cattle vaccine

- Legal requirements
- Containment strategies
- Disinfection and Effluent Treatment methods

P. R. Ramdas, Head - Plant Engineering & HSE, *Intervet, India*

17.30 Chairman's Closing Remarks

18.00 Welcome networking cocktail party

Breakout Stream B

Adjuvants and Delivery Systems

- 13.30 Developing and understanding the effects of novel Adjuvants**
- Adjuvants theory and do we really know the whole story
 - Does the preclinical data back up the clinical and long term studies
 - Can we develop adjuvants which are suitable for both the developed and developing world
- Lakshmi Khandke**, Director, Formulation Development, Pfizer Vaccine Research, USA
- 14.00 Improving prophylactic vaccines using adjuvants**
- The need for adjuvants
 - Evaluating adjuvants in animals
 - Selection of adjuvants
- Bakulesh Khamar**, Executive Director, Research, Cadila Pharmaceuticals, India
- 15.00 Regulatory and scientific considerations when using novel adjuvants or immuno-modulators in vaccine manufacture**
- 15.30 Afternoon refreshments**
- 16.00 Moving from Vials to Pre-fills and the enhanced safety it brings**
- Case study of integrating a pre-fill delivery system into an existing facility
 - Decreasing needle born diseases and the implications that it has on the welfare and development of developing countries
 - Cost comparison of pre-fills vs syringe and vial
- 16.30 Case study of the successful delivery of vaccines via novel delivery systems in India**
- Assessing and selecting the most appropriate delivery system
 - Cost implications- were there any or did the safety benefits outweigh them
 - Challenges and changes required to integrate the new delivery systems into the manufacturing process
 - Future plans
- Rajeev M Dhere**, Senior Director Manufacturing, Serum Institute of India, India
- 17.00 Innovations in needle free vaccine delivery**
- Case studies of recent trials of novel systems in India
 - Case study of influenza vaccine delivery in the USA and Brazil
- Michael Royals**, Chief Scientific Officer, Pharmajet, USA
- 17.30 Chairman closing remarks:**
Reinhard Gluck, CSO, Zydus Cadila, India
- 17.40 Vaccine Summit World day 1 Closes**
- 18.00 Welcome networking cocktail party**

- 9.00 Chairman's opening remarks:**
Kevin P Killeen, VP of Research & Development, *Matrivax Corp.*, USA

Innovation Showcase

- 9.05 Presentation on Science Technology and Innovations in HIV Vaccine R&D**
- Endemic Disease barriers to Economic Growth
 - Harnessing India Innovations for Health R&D
 - IAVI and its India programs
 - The benefits and challenges to drive innovations in health
- Rajat Goyal**, Country Director, IAVI, India
- 9.30 Sabin-IPV: Challenges and Benefits**
- WHO polio eradication program
 - Rationale for Sabin-IPV development
 - History & current status in Sabin-IPV development
 - Clinical/Regulatory aspects
- Dr Arani Chatterjee**, Vice President, *Clinical Research Panacea Biotec*, India
- 9.55 Morning refreshments and networking**
- 10.20 Case study: The challenges of developing a Chikungunya vaccine.**
- K Sumathy**, Associate director of R&D, *Bharat Biotech International Limited*, India
- 10.45 Case study: Advantages of a neonatal dosing schedule and the status of an ongoing Phase II neonatal/infant rotavirus vaccine clinical trial in Ghana**
- Leonard P. Ruiz**, President, *International Medical Foundation*, USA
- 11.10 Case study: The promises of a therapeutic HIV vaccine.**
- Anders Fomsgaard**, Department of Virology, *Statens Serum Institut*, Denmark
- 11.35 Case study: Search for the elusive Cholera Vaccine**
- 12.00 Networking Lunch**
- Funding Innovation in India**
- 13.00 The challenges of getting vaccines from the lab and into production in the developing world**
- Licensing vaccines from not-for-profit research Vs spending on internal research capability
 - The challenges of phase 1; funding, partnerships and production
- Mae Shieh**, Business Development & Partnerships, *Novartis Vaccines Institute for Global Health*, Italy
- 13.25 The Wellcome Trust's commitment to Indian health care**
- An introduction to the R&D for affordable healthcare in India project
 - MSD Wellcome Trust Hilleman Laboratories, a JV not-for-profit organization focusing on unmet medical needs
- Shirshendu Mukherjee**, Strategic advisor, *Wellcome Trust*, India

13.50 Vaccines do they need a new investment model or just patience?**Panel Discussion**

- What can the vaccine industry do to make itself more appealing to venture capital?
- How can developing world vaccine manufacturers become more effective at applying for grants
- PPP is it an option?

Leonard P. Ruiz, President, *International Medical Foundation, USA*

Mae Shieh, Business Development & Partnerships, *Novartis Vaccines Institute for Global Health, Italy*

Rajiv Khanna, Director, *Australian Centre for Vaccine Development, Australia*

Shirshendu Mukherjee, Strategic advisor, *Wellcome Trust, India*

Amit Chander, Head of investments– Healthcare & Pharma, *Baring Private Equity Partners India, India*

14.30 Afternoon refreshment**15.00 Case study: Malaria Vaccines: Hopes, Hurdles & Hopes**

Virander S. Chauhan, Director, *International Centre for Genetic Engineering and Biotechnology, India*

15.25 Using the Animal Rule to make extrapolations of human immunogenicity, before first in man

- An introduction to 21 CFR 314.600 & 21 CFR 601.90 – “Animal Rule”
- Case studies of successful implementation of the Animal Rule and examples of situations during which it would be unethical to determine the efficacy of a vaccine
- Models and methodologies for the Animal Rule

Gurdyal Kalsi, VP Global Clinical Development, *Emergent Biosolutions, UK*

15.50 Case study: Using polyepitope vaccine technology for chronic viral infection

Rajiv Khanna, Director, *Australian Centre for Vaccine Development, Australia*

16.15 Case study: Clinical progress towards an effective dengue vaccine.

Josemund Menezes, Regional Director, Clinical Development (Asia-Pac), *Sanofi-Pasteur, India*

Shaping the future of India's Vaccine Industry**16.35 Hilleman Laboratories: Developing vaccines for resource limited countries**

- Partnerships and technology transfer
- The challenges of creating a novel vaccine which will have a low unit cost when in production
- Selecting which diseases to target that afflict resource limited countries

Altat Lal, CEO, *MSD Wellcome Trust Hilleman Laboratories, India*

17.00 Closing visionary panel discussion: Creating a 5-10 year roadmap for India's Vaccine Industry

- Which direction should the vaccine industry take innovative research or diversify into biologics?
- Factors limiting India's vaccine industry and how they can be addressed
- Preparing for China's SFDA WHO pre-qualification and the impact Chinese vaccine manufacturers will have on the international market
- Programs and initiatives to encourage the next generation of scientists and engineers to become part of the vaccine industry

Altat Lal, CEO, *MSD Wellcome Trust Hilleman Laboratories, India*

K.R.S. Krishnan, Senior Executive Director, *Research and Development and Strategic Planning, HLL Lifecare Limited, India*


Mahima Datta, SVP Biotechnology and projects, *Biological E, India*

C S Jambaladinni, Associate Director (Production), *Ranbaxy Laboratories Limited, India*

1740 Chairman's closing remarks**17.45 Conference closes****Welcome Cocktail Party****Wednesday 6pm, 2 March 2011, Raddison Hotel Delhi**

Having fun makes everything easier... and good food, good drink and good company makes it even easier.

Get to know your peers, become friends, network, laugh, do business; we understand that a fun atmosphere can make a difference. **Vaccine World Summit's welcome cocktail party** is a time to relax, enjoy yourself and get to know people. You never know who you might meet there!

Media Partners

Your Opportunity to Penetrate India's Vaccine Market

Indian vaccine industry has never been playing a more important role than before. It currently caters to 60 to 70 percent of global requirement of basic vaccines procured by U.N. agencies for the children. Furthermore, it is also an important partner in the global initiatives for the development of cost-effective vaccines against emerging threats of swine flu, meningitis, Japanese encephalitis, etc.

On the other hand, are you aware that Indian vaccine manufacturers are looking for new ways to stay competitive and cost effective? Challenges such as "access to new technology", "increasing cost", "inadequate disease burden data in our own country", "funding", "multiple set of regulation and regulators" still remain as major stumbling blocks for Indian vaccine manufacturers to develop more innovative vaccines. It's your ideal opportunity to present your latest technology and product to this market right now!

THE MORE YOU SHOULD BE PART OF IT

- **Get cost-effective marketing exposure** and branding to your target audience.
- **Position and profile** yourself as an industry leader.
- **Enhance your brand recognition** in the Indian and global vaccines industry.
- Create **new partnerships** and alliances
- **Develop & reinforce relationships** through new networking opportunities.
- **Showcase new products** and services to a targeted audience of decision-makers.

No other vaccines event can give you one-to-one access to senior decision-makers from across the entire vaccine value chain from India and globally. Don't settle for second best, get real ROI by being part of the vaccine industry's most comprehensive marketing campaign.

Many industry leading suppliers have already confirmed their participation. If you are committed to the vaccines market, speak to us now.

To find out more about becoming a partner for this event, please contact **Priscilla Liu @+65 64932096** or email: priscilla.liu@imapac.com



Participating Sponsors



Pall Life Sciences Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Pall is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce. Pall's Scientific and Laboratory Services (SLS), Technical Services and Validation Laboratories have been a cornerstone of customer support for over 30 years. The company maintains certified ISO9001

Pall Life Sciences products for the biopharmaceutical industry include:

- Single-use technologies with Pall Allegro™ systems incorporating biocontainers, sterile connectors and disconnectors, sterile and tangential flow filtration capsules, disposable depth filters, and chromatography capsules
- Capsules, cartridges, and housings for prefiltration, sterile filtration, virus reduction, and mycoplasma reduction
- Tangential flow filtration products and systems
- Chromatography sorbents, membrane devices, columns and systems
- Depth filter products in wide selection of formats
- Integrity test instrumentation
- Bioreactor systems
- Quality control instrumentation
- Consulting, training, validation, and instrumentation services manufacturing facilities worldwide.



Headquartered in Golden, CO, USA, PharmaJet was founded in 2005 with the mission to enhance developing world healthcare by providing a safe, affordable and less painful means of vaccine and drug delivery to more people in more places.

With clearances in the US, Europe, Brazil and India, the spring-operated PharmaJet needle-free injection system delivers vaccines and medications in a 0.5mL volume, either intramuscularly or subcutaneously by means of a narrow, high velocity fluid jet, which penetrates the skin.

Compliant with both the ISO 21649 Needle-free Standard and WHO PQS standard the PharmaJet system is simple, cost-effective and robust. The system utilizes an auto-disable single-use syringe, thus eliminating the potential for cross-contamination between patients. Low dead-space volume of the filling adapter and syringe mean minimal waste and efficient use of vaccine resources.

Coming to the Indian market in 2011 is PharmaJet's intradermal injector. This system, based on the currently marketed technology, will permit dose-sparing ID delivery of polio, rabies and other vaccines for which ID delivery has been shown efficacious. The system is designed to enable healthcare workers with little or no training in ID delivery to obtain consistent vaccine delivery to the dermal tissues.

PharmaJet's needle-free injection systems benefit the patient, the healthcare worker and the environment by eliminating needles from the process of vaccine administration and eliminating needle sharps from the environment.

Participating Exhibitors:



Aptar Pharma is the segment within the Aptargroup family dedicated to the pharmaceutical market. We create innovative drug delivery systems that meet the evolving needs of biotechnology, healthcare and pharmaceutical companies around the world.

Aptar Pharma is market driven with a strong focus on specific therapeutic areas such as allergic rhinitis, asthma, COPD, pain management, hormone therapies, mucosal vaccines as well as cough & cold ailments.

The Aptar Pharma Prescription Division specializes in novel drug delivery solutions - i.e. pMDIs, DPLs, Spray Pumps and UnitDoses - specific to physician-prescribed medicines while the Consumer Health Care Division offers dispensing solutions adapted to over-the-counter medications.

Aptar Pharma provides our customers with a wide range of off-the-shelf and personalized proprietary drug delivery technologies and services backed by years of proven expertise.

Our manufacturing facilities are located in Buenos Aires (Argentina), Congers (NY, U.S.A.), Eigeltingen (Germany), Lugano (Switzerland), Le Vaudreuil and Val-de-Reuil (France) and Suzhou (near Shanghai, R.O.C.).

Approximately 6% of Aptar Pharma's annual turnover is dedicated to research, development and industrialization of novel products. Our R&D and Marketing staff work closely together in a global market-focused team of 200 people dedicated to satisfying customer needs. Aptar Pharma R&D centres of excellence are located in Eigeltingen (Germany), Lugano (Switzerland), Le Vaudreuil and Val-de-Reuil (France).

www.aptar.com



1 - 3 March 2011, Raddison Hotel Delhi, New, Delhi, India

Packages	Price until 15th Jan 2011	Price until 4th Feb 2011	Price until 28th Feb 2011	Onsite price	Quantity	Total
3 Day pass**/** 1-3 March 2011 Influenza India + Vaccine World Summit	USD 2,995	USD 3,295	USD 3,495	USD 3,695		
2 Day pass**/** 2-3 March 2011 Vaccine World Summit only	USD 1,995	USD 2,195	USD 2,395	USD 2,695		
3 Day SUPER pass* 1-3 March 2011 Pre-Conference + 2 Day Conference	INR16,000 (see website for availability)	INR16,000 (see website for availability)	INR16,000 (see website for availability)	INR16,000 (see website for availability)		
2 Day SUPER pass* 2-3 March 2011 2 Day conference	INR12,000 (see website for availability)	INR12,000 (see website for availability)	INR12,000 (see website for availability)	INR12,000 (see website for availability)		
Subtotal						

The registration fee includes refreshments, lunch and full conference documentation. The conference fee does not include hotel accommodation. Special discounts and eligibility:

*Applicable strictly ONLY to Indian home grown vaccine companies that conduct vaccine manufacturing or vaccine R&D within India. Please do not make any travel arrangements until we have confirmed your eligibility and registration.

** Academic, government and non-profit organizations enjoy up to 40% off our usual conference pricing.

*** Developing Countries Vaccine Manufacturers' Network's members will enjoy a special 50% discount.

*** Send your team and save more! 3 delegates, save 10%; 5 delegates, save 20%

***ONLY one discount scheme is applicable

To confirm your eligibility, please email: lisa.tan@imapac.com

Your Details

Name _____
 Jobtitle _____ Organization _____
 Address _____
 Postcode _____ Country _____
 Tel _____ Fax _____
 Email _____
 Your primary business _____
 Authorising Manager _____ Authorising manager signature _____
 By signing and returning this form, you are accepting our terms and conditions.

Payment Details

Payment is due immediately upon receipt of this registration form if you pay by credit card or three working days after your receipt of payment notification. Offline payments will incur an additional US\$100.

I want to pay Online Offline and add USD100 booking fee:

Online Payments:

Visa MasterCard American Express Diners Discover

Please register at: <http://www.imapac.com/vaccineindia2011>

Offline payments:

Bank transfer: Payment by bank transfer must quote delegate name and conference name. For bank details and swift code, please email lisa.tan@imapac.com.

Crossed cheque payable to IMAPAC Pte Ltd, and mail it in a sealed envelope to IMAPAC Pte Ltd, 8 Eu Tong Sen Road, #17-86 The Central, Singapore 059818

American Express

Name on Card _____ Card Number _____

Expiry Date _____ Signature _____

Event Venue



Date: 1 -3 March 2011

Venue: Raddison Hotel Delhi
National Highway-8, New Delhi 110037, India

4 Easy Ways to Register

Online

The quickest and easiest way to register is online using a credit card. Visit <http://www.imapac.com/vaccineindia2011> and click on register now

Telephone

To register over the phone, please call us on +65 64932093

By Fax

Please fax your booking form to +65 6826 4316

Mail

By Cheque made payable to: IMAPAC PTE. LTD
Send with this booking form to: IMAPAC PTE. LTD.
8 Eu Tong Sen Street, #17-86
The Central, Singapore 059818

Group Booking

Send your team and save more!

3 delegates, save 10%

5 delegates, save 20%

Call +65 64932093 or go online and register at <http://www.imapac.com/vaccineindia2011>

Terms and Conditions

- Full payment is due upon registration if you pay by credit card, or 3 working days after receipt of invoice.
- Registration will not be confirmed until full payment has been received.
- Unpaid registration will be billed 50% of the registration fee if you do not attend the event. A copy of the conference documentation will be mailed to you.
- The registration fee includes refreshments, lunches, cocktails and full conference documentation. The conference fee does not include hotel accommodation.
- Staff at the event will request a credit card guarantee for delegates without proof of payment.

Cancellation and Substitution Policy

- Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee.
- A substitution from the same organisation can be made at any time in writing at no extra charge.
- In the event that IMAPAC cancels a conference, payments received at the cancellation date will be credited towards attendance at a future conference or in the event of postponement by IMAPAC, towards the rescheduled date.
- Credit notes remain valid for twelve months.

CHANGES TO CONFERENCE & AGENDA IMAPAC reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers for an event. IMAPAC is not responsible for any loss or damage as a result of substitution, alteration, postponement or cancellation of an event due to causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

In the event that a conference is cancelled, IMAPAC is not liable for any costs incurred by delegates in connection with their attendance. Occasionally it is necessary for reasons beyond our control to alter the content and timing of the programme, venue or the identity of the speakers without any liability to the delegates. Changes to the agenda will be updated on our website as soon as possible.

DATA PROTECTION The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to reputable third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: data@imapac.com